Mix and Match of the COVID-19 Vaccine for Safety and Immunogenicity (NCT04894435)
Immunogenicity and Adverse Events Following Immunization (AEFI) With Alternate Schedules of COVID-19 Vaccines in Canada: is "Mix and Match" of the Second Dose (MOSAIC-1;CT24a) and Additional Doses (MOSAIC-2 and MOSAIC-3;CT24b and CT24c) Safe and Immunogenic?
🩺 Plain-English Summary (8th-Grade Level)
The main goals of this study are to assess the immune response and safety of two different vaccines for first, second, third and fourth doses as well as for differing intervals between the first and second dose of two-dose vaccines.
Who can join: Review the eligibility criteria below.
Location: Royal Inland Hospital — Kamloops, British Columbia
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (8 Sites)
- Royal Inland Hospital — Kamloops, British Columbia
- Penticton Regional Hospital — Penticton, British Columbia
- BC Children's Hospital Research Institute — Vancouver, British Columbia
- Children's Hospital Research Institute of Manitoba — Winnipeg, Manitoba
- Canadian Center for Vaccinology — Halifax, Nova Scotia
- Ottawa Hospital Research Institute, University of Ottawa — Ottawa, Ontario
- McGill University Health Centre Vaccine Study Centre — Montreal, Quebec
- CHU de Québec, Université Laval — Québec, Quebec
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in COVID-19
- COVID-19 and Cancer Consortium Registry — Nashville, Tennessee
- Impact of Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients — Sacramento, California
- COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE) — Bethesda, Maryland
- Identification and Characterization of SARS-CoV-2 Specific CD8 T Cells in Humans — Baltimore, Maryland
- Canadian Adaptive Platform Trial of Treatments for COVID-19 in Community Settings — Calgary, Alberta
- A Nasal Treatment for COVID-19 — Indianapolis, Indiana
Explore by condition: All COVID-19 clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.